Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 11/20 | 0.54 |
| ▸ | CA2 | P00918 | 11/20 | 0.54 |
| ▸ | CA9 | Q16790 | 11/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5922300 | 0.77 | PLK1 (0.67) | PLK1CA1CA2CA9CNR2 | |
| SCHEMBL11962153 | 0.77 | PLK1 (1.00) | PLK1CA1CA2CA9CNR2 | |
| SCHEMBL13794378 | 0.76 | MCHR1 (0.58) | PLK1 | |
| SCHEMBL2856642 | 0.75 | HPGD (0.63) | NPC1RIPK1POLB | |
| SCHEMBL16404255 | 0.75 | CNR1 (0.70) | CNR2HTR2AHTR2CSLC6A4RIPK1 | |
| SCHEMBL5922333 | 0.74 | PLK1 (0.75) | PLK1CA1CA2CA9CNR2 | |
| SCHEMBL3262582 | 0.74 | NPC1 (0.53) | NPC1HTR2AHTR2CSLC6A4POLB | |
| SCHEMBL2449412 | 0.73 | PLK1 (0.73) | PLK1CA1CA2CA9 | |
| SCHEMBL561184 | 0.73 | RXFP1 (0.47) | CNR2NPC1HTR2AHTR2CSLC6A4 | |
| SCHEMBL6175361 | 0.73 | NPC1 (0.61) | NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1432679-A1 | PREPARATION AND USE OF PYRROLE DERIVATIVES FOR TREATING OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027069-A1 | PREPARATION AND USE OF PYRROLE DERIVATIVES FOR TREATING OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | PGC, GIPR, GPR119 | PLK1 1601/4885CA1 4395/4885CA2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.